# Claude Opus 4.8 / inf-k01

Original final answer, shared by both scoring rounds.

# From GWAS Association to Effector Gene: The Inferential Chain

## Bottom Line

Given E1 alone — a lead noncoding SNP near gene G, several linked variants spanning G and H, and no functional or colocalization data — **you cannot yet name a causal variant or an effector gene.** The association is real but localizes a *region*, not a variant, and proximity to G does not establish that G (rather than H or a more distant gene) is the effector. Each subsequent method (fine mapping, colocalization, functional perturbation) narrows a specific uncertainty but leaves others open. Below is the chain, step by step, with what each link can and cannot establish.

---

## Step 1: GWAS Association → Linkage (what E1 gives you)

**Evidence (E1):** A well-controlled GWAS associates a lead noncoding SNP with the trait; several variants spanning G and H are linked.

**Inference:** The statistical signal reflects a true association between genotype at this locus and phenotype. But the lead SNP is almost never special on its own — it is correlated (in **linkage disequilibrium, LD**) with many neighboring variants that co-segregate in the population.

**What this establishes:**
- A genomic *interval* harbors at least one causal variant influencing the trait.
- "Well-controlled" implies population stratification, relatedness, and major confounders have been addressed, so the signal is unlikely to be a spurious artifact.

**What this cannot establish:**
- *Which* variant is causal. The lead SNP may simply be the best-genotyped or best-imputed tag for an unobserved causal variant.
- *Which gene* is the effector. "Near gene G" is a proximity heuristic, not a mechanism. Regulatory variants frequently act on genes that are not the closest — through long-range enhancer–promoter contacts.
- *Direction of biology* (whether the trait-raising allele increases or decreases gene activity).

**Key concept — LD is the central confounder:** Because linked variants rise and fall together across individuals, association statistics cannot, by themselves, separate a causal variant from its correlated passengers. This is why the lead SNP being noncoding and sitting near G does not privilege either that SNP or that gene.

---

## Step 2: Fine Mapping → A Credible Set of Variants

**What it does:** Fine mapping uses the LD structure and the association statistics (ideally with dense genotyping/imputation and a matched LD reference) to compute, for each variant, a posterior probability of being causal. The output is a **credible set** — the smallest group of variants that collectively has, say, ≥95% probability of containing the causal variant.

**Evidence-to-inference-to-conclusion:**
- *Evidence:* association strengths plus LD among the variants spanning G and H.
- *Inference:* variants in high LD with the signal but inconsistent with the fine-mapping model are downweighted; those most consistent retain high posterior probability.
- *Conclusion:* a ranked, probabilistic shortlist of candidate causal variants.

**What this can establish:**
- A reduced set of plausible causal variants, sometimes narrowing to a handful or even one.

**What this cannot establish:**
- **Fine mapping does not identify the effector gene.** It operates on variants, not transcripts. A credible set spanning G and H still does not say which gene is perturbed.
- Resolution fails when LD is strong: if several variants are near-perfectly correlated, they remain statistically indistinguishable regardless of sample size. The credible set stays large.
- It assumes a single (or specified number of) causal signal(s) and a correctly matched LD reference; mismatched LD panels can mislead.
- It presumes the true causal variant was genotyped or well-imputed. If not, the credible set may center on tags rather than the real driver.

**Caution for E1:** With no additional data supplied, we have not actually run fine mapping — we only know the inputs permit it in principle. We cannot assert a credible set here.

---

## Step 3: Colocalization → Linking the Signal to a Molecular Phenotype and a Gene

**What it does:** Colocalization tests whether the GWAS association and a molecular QTL association (e.g., an eQTL for gene G or H, or a splicing/protein QTL) in a relevant tissue are driven by the **same** underlying causal variant, rather than by two distinct variants that happen to be in LD.

**Evidence-to-inference-to-conclusion:**
- *Evidence:* overlapping GWAS and QTL association patterns across the same variants, analyzed jointly.
- *Inference:* high posterior support for a shared causal variant implies the trait signal acts *through* that molecular phenotype — e.g., through expression of gene G in a specific tissue.
- *Conclusion:* a mechanistic hypothesis — *this variant affects the trait by regulating this gene in this tissue.*

**What this can establish:**
- A credible *nomination* of the effector gene (G vs. H) and the molecular mechanism (expression, splicing) and the relevant tissue.
- It directly addresses the gene-assignment gap that fine mapping leaves open.

**What this cannot establish:**
- **Colocalization is still correlational.** Sharing a causal variant is consistent with causation but does not prove the QTL mediates the trait; both could be downstream of a third mechanism, or the colocalization could reflect residual LD not fully resolved.
- It requires QTL data in the **right tissue, cell type, and state**. A gene can be the true effector yet show no eQTL in the assayed context (e.g., effect only under stimulation or in a rare cell type), producing a false negative.
- Distinct causal variants in tight LD can masquerade as colocalized or, conversely, fail to colocalize despite real biology.

**Caution for E1:** **No colocalization data are supplied.** Therefore we cannot, from this packet, assign G or H as the effector gene or name a tissue. Proximity to G remains a hypothesis only.

---

## Step 4: Functional Perturbation → Causal Test of Variant and Gene

**What it does:** Experimental manipulation closes the causal gap that statistics cannot. Two distinct questions require two kinds of experiments:

1. **Does the candidate *variant* have a regulatory effect?** Assays such as reporter assays (e.g., MPRA), allele-specific expression, or base/prime editing of the single variant in a relevant cell type test whether swapping the allele changes regulatory activity or gene expression.
2. **Is the nominated *gene* the effector for the trait?** Perturbing the gene (CRISPR knockout/knockdown/activation, CRISPRi of the enhancer) and measuring a trait-relevant cellular phenotype tests whether the gene — not merely the variant — drives the biology.

**Evidence-to-inference-to-conclusion:**
- *Evidence:* an allele-specific or gene-specific change in a relevant readout upon targeted perturbation.
- *Inference:* the variant/gene is *sufficient* and/or *necessary* for the molecular or cellular effect.
- *Conclusion:* causal validation of the variant's regulatory activity and/or the gene's role.

**What this can establish:**
- The strongest level of causal support available: that editing the specific allele changes gene regulation, and that the gene's activity changes a trait-relevant phenotype.

**What this cannot establish:**
- A cellular or molecular phenotype is **not the organismal trait**. Demonstrating that the variant alters G's expression and that G affects a cell phenotype still requires an argument (or model system) linking that phenotype to the human trait.
- Perturbation effects are **context-dependent**: a null result in one cell type or condition does not exclude causality in another.
- Over-expression/knockout can produce effects at doses far from the subtle regulatory shift a common variant causes, risking non-physiological conclusions.

---

## Integrated Chain and Honest Endpoint for E1

| Step | Input evidence | What it establishes | What remains open |
|---|---|---|---|
| GWAS/LD (E1) | Association + linked variants over G, H | A causal interval exists | Which variant; which gene |
| Fine mapping | Association + LD | Probabilistic credible set of **variants** | Effector gene; mechanism |
| Colocalization | GWAS + QTL | Nominates **gene + tissue + molecular mechanism** | True mediation; context gaps |
| Functional perturbation | Editing/perturbation assays | Causal effect of **variant and/or gene** on a readout | Link readout → organismal trait |

**Conclusion from the supplied packet:** E1 licenses only the first row. We have a genuine, well-controlled association pointing to a region containing G and H. We **cannot** name the causal variant (fine mapping not performed), **cannot** assign the effector gene (no colocalization; proximity to G is insufficient and does not exclude H or a distant gene), and **cannot** claim functional causality (no perturbation). The reproduced figures are synthetic teaching materials and provide no additional validation.

**Recommended next actions, in order:** (1) fine-map to obtain a credible set; (2) colocalize with eQTL/sQTL/pQTL data in trait-relevant tissues to nominate G vs. H and a mechanism; (3) functionally perturb the top variant and nominated gene in an appropriate cellular model, then argue explicitly how the cellular readout connects to the trait. Each step reduces a specific, named uncertainty; none alone completes the chain.
